BioSpace News Archive

Women seeking to start or expand a family can now access the Proov Confirm PdG home collection kit for assessing fertility through questhealth.com.

South Rampart Pharma, Inc. (“South Rampart” or the “Company”) today announced that the China National Intellectual Property Administration (CNIPA) has granted the Company a new patent covering the composition of matter of SRP-001, South Rampart’s novel, non-opioid new chemical entity that avoids the liver toxicity associated with acetaminophen.

Altamira Therapeutics Ltd. announced today the pricing of a public offering of 11,111,112 common shares (or pre-funded warrants in lieu thereof) accompanied by common warrants to purchase up to 11,111,112 common shares, at a combined public offering price of $0.45 per share.

Audax Private Equity (“Audax”), a leading alternative investment manager and capital partner for North American middle market companies, announced today it has entered into a definitive agreement to sell CorEvitas, LLC (“CorEvitas”), a leading provider of real-world evidence for regulatory approved medical treatments and therapies, to Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”).

Hillstream BioPharma, Inc. today announced the signing of an exclusive agreement with Applied Biomedical Science Institute (ABSI) to license technology for human antibodies targeting novel HER2 and HER3 Conformational Epitopes.

Stryker announced the launch of its Ortho Q Guidance system, the only fully autonomous system in the industry, easily controlled by the surgeon from the sterile field.

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, has been granted full Marketing Authorization (MA) by the European Commission in the European Union (EU) for Nuvaxovid™ (NVX-CoV2373).

Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company’s results for the quarter ended March 31, 2023.

IPS HEART today announced that the U.S. Food and Drug Administration (FDA) awarded a third Rare Pediatric Drug Designation (RPDD) for its product candidate, ISX9-CPC, for treatment of cardiomyopathy associated with Danon disease.

Sensus Healthcare, Inc. announces a partnership with MIS Healthcare to distribute Sensus’ superficial radiation therapy products in the United Kingdom and Ireland.